Welcome to our dedicated page for xspa news (Ticker: xspa), a resource for investors and traders seeking the latest updates and insights on xspa stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect xspa's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of xspa's position in the market.
XpresSpa Group has opened a new COVID-19 testing facility named XpresCheck at San Francisco International Airport (SFO). This facility, located pre-security in Terminal 3, boasts nine testing rooms with the capacity to administer over 500 tests daily, including Rapid Molecular tests and standard PCR tests. The company aims to provide convenient testing options for travelers, particularly those flying with United Airlines and Hawaiian Airlines. XpresSpa currently operates testing facilities in multiple airports across the U.S.
XpresSpa Group has launched its first XpresCheck COVID-19 testing facility at Seattle-Tacoma International Airport (SEA), enhancing access for travelers pre-security. This facility features eight testing rooms capable of administering over 500 tests daily, including Rapid Molecular and PCR tests. Appointments are available for ticketed passengers up to 72 hours before travel, with operations from 8 a.m. to 5 p.m. daily. The initiative aims to facilitate safer travel and aligns with testing requirements for flights to Hawaii.
XpresSpa Group, Inc. (Nasdaq: XSPA) announced plans to open a new COVID-19 testing facility at San Francisco International Airport, expected to launch in mid-April 2021. The facility, located pre-security at Terminal 3, will feature nine testing rooms and a testing capacity of over 500 tests daily, offering both Rapid Molecular and PCR tests. CEO Doug Satzman emphasized the partnership with United Airlines to enhance travel safety, coinciding with increasing travel demand. This development aligns with United's commitment to provide testing for passengers to meet entry requirements.
XpresSpa Group (Nasdaq: XSPA) announced the addition of a new rapid antigen test for COVID-19 as part of its expanded testing offerings. This initiative includes an agreement with Delta Air Lines to provide testing for passengers traveling from JFK International Airport to Milan and Rome. The new test aims to increase efficiency and safety for travelers, with flights to Milan set to operate four times weekly, increasing in frequency over time. XpresCheck currently operates in nine airports, providing essential testing services during the pandemic.
XpresSpa Group (XSPA) updates on business growth as eleven XpresCheck Wellness Centers currently operate, with two more locations set to open soon. The company plans to launch a new travel health and wellness brand by late summer/early fall 2021. XpresSpa reported a cash balance of approximately $90 million as of December 31, 2020. Recent testing volumes show a significant recovery, with a gross profit margin exceeding pre-pandemic levels. However, revenue for Q4 2020 was only $0.3 million, a substantial decline from $10.9 million in the same period in 2019.
XpresSpa Group (Nasdaq: XSPA) is expanding its COVID-19 testing capabilities by introducing rapid PCR-based tests at airport locations, starting with JFK and Houston's George Bush Intercontinental Airport. This initiative utilizes the FDA-authorized Accula SARS-CoV-2 Test, providing results in just 30 minutes. According to CEO Doug Satzman, this expansion aims to facilitate safe air travel as it resumes post-pandemic. The company operates testing locations in eleven airports, and this move enhances its commitment to ensuring the health of travelers and airport personnel.
XpresSpa Group, Inc. (Nasdaq: XSPA) has announced its plans to report its fourth quarter and full year 2020 financial results on March 31, 2021, after market close. The company will also file its SEC Form 10-K for the year ending December 31, 2020. Following the announcement, a webcast and conference call will take place at 4:30 PM ET.
Investors can access the presentation via the Investor Relations section of XpresSpa's website. The company operates 45 locations in 23 airports globally, providing spa services and health products.
XpresSpa Group (Nasdaq: XSPA) has opened two XpresCheck™ COVID-19 Testing Facilities at Dulles International and Reagan National Airports, enhancing travel convenience as demand for testing rises. Each facility will serve all passengers, featuring separate testing rooms for rapid and PCR tests. At Dulles, over 500 tests can be administered daily, while Reagan can handle over 300 tests. This initiative aims to restore passenger confidence in air travel and is expected to support the company's growth in the health and wellness sector.
XpresSpa Group, Inc. (Nasdaq: XSPA) recently opened its first XpresCheck testing facility in Texas at Houston George Bush Intercontinental Airport, in partnership with United Airlines. This facility aims to provide COVID-19 testing, with a capacity of over 300 tests daily, including Rapid Molecular and PCR tests. CEO Doug Satzman expressed excitement over enhancing traveler safety and convenience. The venture continues to expand the company's COVID-19 testing services, now available at nine locations across seven airports.
XpresSpa Group has announced the launch of its first XpresCheck COVID-19 testing facility on the West Coast, located at Seattle-Tacoma International Airport. Expected to begin operations by mid-March, the facility will feature eight testing rooms with a capacity for over 500 tests daily, offering both Rapid Molecular and PCR tests. This expansion strengthens XpresSpa's commitment to providing accessible testing services, particularly for travelers to Hawaii, and aligns with its long-term goals in the travel health and wellness sector.
FAQ
What is the market cap of xspa (xspa)?
